MOUNTAIN VIEW, Calif., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure ® procedure, the leading surgery-free permanent birth control method, announced today that Company management is planning to present at the 25th Annual ROTH Conference on Tuesday, March 19, 2013 at 11:30 a.m. Pacific time at the Ritz-Carlton Hotel in Laguna Niguel, California.
A live webcast of the presentation will be available on the company's website at www.conceptus.com . When accessing the webcast through the Conceptus site, select "Investors" then select "Events and Presentations." The archived replay will be available following the live presentation.
About the Essure ® ProcedureThe Essure procedure, FDA approved since 2002, is the only surgery-free and hormone-free permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body works with the inserts to form a natural barrier in the fallopian tubes to prevent sperm from reaching the egg. Three months after the Essure procedure, an Essure Confirmation Test is given to confirm that the inserts are in place and that the fallopian tubes are blocked, verifying that the patient can rely on Essure for permanent birth control. The Essure procedure is 99.83% effective based on five years of follow up with zero pregnancies reported in clinical trials, making it the most effective permanent birth control available. Essure's 10-year commercial data tracks closely with its five-year clinical results, and Essure has been proven and trusted by physicians since 2002. The Essure procedure is covered in the U.S. by most public and private insurance plans and approximately 730,000 women worldwide have undergone the procedure.